LONDON/TOKYO -- A coronavirus vaccine being developed by British pharmaceutical AstraZeneca and Oxford University showed a robust immune response in the early phases of its trial.
The company is expected to begin trials in Japan in August as the world waits for a vaccine to stop the pandemic.
